Atherothrombosis model by silencing of protein C in APOE3-Leiden.CETP transgenic mice

• Published in: Journal of thrombosis and thrombolysis 2021-10, Vol.52 (3), p.715-719
• Main Authors: Jongejan, Yvonne K., Eikenboom, Jeroen C. J., Gijbels, Marion J. J., Berbée, Jimmy F. P., van Vlijmen, Bart J. M.
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Aorta; Apolipoprotein E; Apolipoproteins; Apolipoproteins E; Arteriosclerosis; Atherosclerosis; Atherosclerosis - genetics; Cardiology; Cholesterol Ester Transfer Proteins - genetics; Cholesteryl ester transfer protein; Drug development; Female; Fibrin; Hematology; Hyperlipidemia; Hyperlipoproteinemia; Injection; Lesions; Lipids; Medicine; Medicine & Public Health; Mice; Mice, Transgenic; Pharmaceutical Preparations; Phenotypes; Plaques; Protein C; Proteins; siRNA; Thrombosis; Transgenic animals; Transgenic mice
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-021-02488-2

Murine atherosclerosis models are key for investigation of atherosclerosis pathophysiology and drug development. However, they do not feature spontaneous atherothrombosis as a final stage of atherosclerosis. Transgenic mice expressing both the human mutant apolipoprotein E form APOE*3-Leiden and human cholesteryl ester transfer protein ( CETP ), i.e. APOE*3-Leiden.CETP mice, feature a moderate hyperlipoproteinemia and atherosclerosis phenotype. In contrast to apolipoprotein E deficient ( Apoeˉ / ˉ ) mice, APOE*3-Leiden.CETP mice respond well to lipid-lowering and anti-atherosclerotic drugs. The aim of the study was to investigate whether silencing of anticoagulant Protein C ( Proc ) allows APOE*3-Leiden.CETP mice to feature thrombosis as a final stage of atherosclerosis. Female APOE*3-Leiden.CETP mice were fed a Western-type diet to induce advanced atherosclerosis, followed by an injection with a small interfering RNA targeting Proc (si Proc ). Presence of atherosclerosis and atherothrombosis was determined by histologic analysis of the aortic root. Atherosclerosis severity in the aortic root area of APOE*3-Leiden.CETP mice varied from type “0” (no lesions) to type “V” lesions (advanced and complex lesions). Atherothrombosis following si Proc injection was observed for 4 out of 21 APOE*3-Leiden.CETP mice (19% incidence). The atherothrombosis presented as large, organized, fibrin- and leukocyte-rich thrombi on top of advanced (type “V”) atherosclerotic plaques in the aortic root. This atherothrombosis was comparable in appearance and incidence as previously reported for Apoeˉ / ˉ mice with a more severe atherosclerosis (19% incidence). APOE*3-Leiden.CETP mice with modest hyperlipidemia and atherosclerosis can develop atherothrombosis upon transient Proc -silencing. This further extends the use of these mice as a test model for lipid-lowering and anti-atherosclerotic drugs.